Bio Path Holdings Stock Today
| BPTH Stock | USD 2.56 0.16 5.88% |
Performance0 of 100
| Odds Of DistressOver 84
|
Bio Path is trading at 2.56 as of the 13th of May 2024. This is a -5.88 percent decrease since the beginning of the trading day. The stock's open price was 2.72. Bio Path has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Bio Path Holdings are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 13th of April 2024 and ending today, the 13th of May 2024. Click here to learn more.
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas. Bio-Path Holdings operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 1.57 M outstanding shares of which 44.38 K shares are currently shorted by private and institutional investors with about 0.01 trading days to cover. More on Bio Path Holdings
Moving together with Bio Stock
| 0.84 | KA | Kineta Inc | PairCorr |
| 0.61 | VAXX | Vaxxinity Financial Report 14th of May 2024 | PairCorr |
Moving against Bio Stock
| 0.83 | YS | YS Biopharma | PairCorr |
| 0.8 | VERU | Veru Inc Fiscal Year End 13th of December 2024 | PairCorr |
| 0.55 | DOMH | Dominari Holdings | PairCorr |
Bio Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Bio Path's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Bio Path or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Pharmaceutical Products, Biotechnology, Healthcare, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Bio Path Holdings (BPTH) is traded on NASDAQ Exchange in USA. It is located in 4710 Bellaire Boulevard, Bellaire, TX, United States, 77401 and employs 10 people. Bio Path is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.26 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bio Path's market, we take the total number of its shares issued and multiply it by Bio Path's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Bio Path Holdings conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.57 M outstanding shares of which 44.38 K shares are currently shorted by private and institutional investors with about 0.01 trading days to cover.
Bio Path Holdings currently holds about 17.02 M in cash with (11.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.38.
Check Bio Path Probability Of Bankruptcy
Ownership AllocationAlmost 98.0 percent of Bio Path outstanding shares are held by general public with 0.1 (percent) owned by insiders and only 1.75 % by other corporate entities.
Check Bio Ownership Details
Bio Stock Price Odds Analysis
Coming from a normal probability distribution, the odds of Bio Path jumping above the current price in 90 days from now is about 86.71%. The Bio Path Holdings probability density function shows the probability of Bio Path stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Bio Path Holdings has a beta of -1.2765 suggesting as returns on its benchmark rise, returns on holding Bio Path Holdings are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Bio Path is expected to outperform its benchmark. Additionally, bio Path Holdings has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Bio Path to move above the current price in 90 days from now is about 86.71 (This Bio Path Holdings probability density function shows the probability of Bio Stock to fall within a particular range of prices over 90 days) .
Bio Path Holdings Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Bio Path market risk premium is the additional return an investor will receive from holding Bio Path long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Bio Path. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Bio Path's alpha and beta are two of the key measurements used to evaluate Bio Path's performance over the market, the standard measures of volatility play an important role as well.
| Risk Adjusted Performance | (0.10) | |||
| Jensen Alpha | (1.44) | |||
| Total Risk Alpha | (2.45) | |||
| Treynor Ratio | 1.2 |
Bio Stock Against Markets
Picking the right benchmark for Bio Path stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Bio Path stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Bio Path is critical whether you are bullish or bearish towards Bio Path Holdings at a given time. Please also check how Bio Path's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Bio Path without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Competition Analyzer Now
Competition AnalyzerAnalyze and compare many basic indicators for a group of related or unrelated entities |
| All Next | Launch Module |
Bio Path Corporate Management
Elected by the shareholders, the Bio Path's board of directors comprises two types of representatives: Bio Path inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bio. The board's role is to monitor Bio Path's management team and ensure that shareholders' interests are well served. Bio Path's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bio Path's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael MBA | VP Operations | Profile | |
| Alan MacKenzie | Consultant | Profile | |
| Thomas Walker | Consultant | Profile | |
| MBA Ashizawa | Development Research | Profile | |
| Peter MBA | Chairman, CoFounder | Profile | |
| Jeffery MD | Consultant | Profile | |
| Victoria Rac | Regulatory Consultant | Profile |
How to buy Bio Stock?
Before investing in Bio Path, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Bio Path. To buy Bio Path stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Bio Path. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Bio Path stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Bio Path Holdings stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Bio Path Holdings stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Bio Path Holdings, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Bio Stock please use our How to Invest in Bio Path guide.
Already Invested in Bio Path Holdings?
The danger of trading Bio Path Holdings is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Bio Path is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Bio Path. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Bio Path Holdings is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Bio Path Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Path's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Path Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Path Holdings Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Path Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Bio Stock analysis
When running Bio Path's price analysis, check to measure Bio Path's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Path is operating at the current time. Most of Bio Path's value examination focuses on studying past and present price action to predict the probability of Bio Path's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Path's price. Additionally, you may evaluate how the addition of Bio Path to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is Bio Path's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.